These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33374949)

  • 1. Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma.
    Sato T; Kawasaki Y; Maekawa M; Takasaki S; Morozumi K; Sato M; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
    Metabolites; 2020 Dec; 11(1):. PubMed ID: 33374949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of Metabolomic Changes in Sunitinib-Resistant Human Renal Carcinoma 786-O Cells by Capillary Electrophoresis-Time of Flight Mass Spectrometry.
    Hatakeyama H; Fujiwara T; Sato H; Terui A; Hisaka A
    Biol Pharm Bull; 2018; 41(4):619-627. PubMed ID: 29607935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melatonin suppresses Akt/mTOR/S6K activity, induces cell apoptosis, and synergistically inhibits cell growth with sunitinib in renal carcinoma cells via reversing Warburg effect.
    Xue KH; Jiang YF; Bai JY; Zhang DZ; Chen YH; Ma JB; Zhu ZJ; Wang X; Guo P
    Redox Rep; 2023 Dec; 28(1):2251234. PubMed ID: 37642220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidation and Regulation of Tyrosine Kinase Inhibitor Resistance in Renal Cell Carcinoma Cells from the Perspective of Glutamine Metabolism.
    Morozumi K; Kawasaki Y; Sato T; Maekawa M; Takasaki S; Shimada S; Sakai T; Yamashita S; Mano N; Ito A
    Metabolites; 2024 Mar; 14(3):. PubMed ID: 38535330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NT5E inhibition suppresses the growth of sunitinib-resistant cells and EMT course and AKT/GSK-3β signaling pathway in renal cell cancer.
    Peng D; Hu Z; Wei X; Ke X; Shen Y; Zeng X
    IUBMB Life; 2019 Jan; 71(1):113-124. PubMed ID: 30281919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
    Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
    Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant.
    Tsuruda M; Yoshino H; Okamura S; Kuroshima K; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    PLoS One; 2020; 15(5):e0232545. PubMed ID: 32379831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma.
    Sekino Y; Sakamoto N; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
    Oncology; 2019; 97(3):164-172. PubMed ID: 31195398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Linkage of Drug Resistance and Metabolome Shift in Renal Cell Carcinoma Cells].
    Sato H
    Yakugaku Zasshi; 2020; 140(8):963-968. PubMed ID: 32741869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
    Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
    EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
    Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines.
    Mizumoto A; Yamamoto K; Nakayama Y; Takara K; Nakagawa T; Hirano T; Hirai M
    J Pharmacol Exp Ther; 2015 Nov; 355(2):152-8. PubMed ID: 26306766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trichostatin A modulates cellular metabolism in renal cell carcinoma to enhance sunitinib sensitivity.
    Sato H; Uzu M; Kashiba T; Fujiwara T; Hatakeyama H; Ueno K; Hisaka A
    Eur J Pharmacol; 2019 Mar; 847():143-157. PubMed ID: 30689992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
    Sakai I; Miyake H; Fujisawa M
    BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib induces early histomolecular changes in a subset of renal cancer cells that contribute to resistance.
    Lichner Z; Saleeb R; Butz H; Ding Q; Nofech-Mozes R; Riad S; Farag M; Varkouhi AK; Dos Santos CC; Kapus A; Yousef GM
    FASEB J; 2019 Jan; 33(1):1347-1359. PubMed ID: 30148679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential therapeutic target secretogranin II might cooperate with hypoxia-inducible factor 1α in sunitinib-resistant renal cell carcinoma.
    Fukumoto W; Yoshino H; Horike SI; Kawakami I; Tamai M; Arima J; Kawahara I; Mitsuke A; Sakaguchi T; Inoguchi S; Meguro-Horike M; Tatarano S; Enokida H
    Cancer Sci; 2023 Oct; 114(10):3946-3956. PubMed ID: 37545017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
    Juengel E; Kim D; Makarević J; Reiter M; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2015 Feb; 19(2):430-41. PubMed ID: 25444514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgelin Contributes to a Poor Response of Metastatic Renal Cell Carcinoma to Sunitinib Treatment.
    Bouchalova P; Beranek J; Lapcik P; Potesil D; Podhorec J; Poprach A; Bouchal P
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MIER2/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma.
    Wei Z; Ye Y; Liu C; Wang Q; Zhang Y; Chen K; Cheng G; Zhang X
    J Adv Res; 2024 May; ():. PubMed ID: 38702028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.